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                                                        ABSTRACT 
Background: 
Obesity  is a known risk factor for several chronic disease including hypertension, 
type 2 diabetes, dislipidemoia and coronary heart diseases.(must et al and modad et al 
1999). Adipose tissue associated with obesity is known to secrete numerous 
proinflammatory cytokines such as IL-1 and TNF-α.these proinflammatory cytokines 
may play a crucial role in the close relationship among obesity, periodontitis and chronic 
diseases. (beck and offenbecher 2005) 
Aim: 
The aim of the present study was to determine whether obesity, which is 
associated with the development of number of chronic diseases, acts as a contributing 
factor in the development or progression of periodontal disease.   
Materials and methods: 
A total of 100 patients was include in the study with age group ranging from 18-
59 years. They were divided into the younger 18-34 year olds and the middle aged 35-59 
year old subjects. They were further subdivided based upon their BMI. The cutoff value 
for BMI was 23. Subjects WH ratio was also measured. Venous blood samples were 
collected for TC, TG, HDL, LDL and HsCRP. Periodontal parameters included were 
CAL, BI, PD were recorded in full mouth basis at 6 sites per tooth. 
Results: 
There was a positive correlation between increasing BMI andWH ratio values 
with the severity of CAL but the association was not statistically significant. TC, TG, 
HDL were vwithin the normal limits among the study subjects. There was a significant 
association between HsCRP in the younger age group whose BMI was 30.97±6.14. 
Conclusion: 
In this study, there was a positive correlation between indicators of obesity such 
as BMI and W:H ratio with the severity of periodontal disease but the association was not 
statistically significant. There may be a weak association between periodontitis and 
obesity. Further longitudinal studies are required to determine the association between 
obesity and periodontitis.  
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              INTRODUCTION 
      Periodontitis is an inflammatory disease induced by bacterial biofilms that 
accumulate in the gingival margin, in which a series of aberrant inflammatory responses 
are initiated in the periodontal tissues ( Kornman et al, 1997). Interaction of the bacteria 
with the host results in an immuno-inflammatory response in the adjacent host tissues and 
triggers the release of numerous inflammatory mediators such as cytokines, some of 
which leads to the destruction of periodontal structures including supporting tissues of the 
teeth, alveolar bone and periodontal ligament.  
Although bacterial pathogens are required to initiate the disease process, their 
presence alone is not sufficient to cause the tissue destruction that occurs in periodontitis 
(William RC 1990, Birkedal – Hansen, 1993). The rate of progression may be modified 
by the presence of one or more risk factors such as smoking (Bergstrom et al 2000), 
diabetes mellitus (Genco et al 1996), genetic  disorders (Hart TC et al 1994, Sofaer et 
al 1990), stress (Genco and Grossi et al 1999), hyperlipidaemia ( Ozlan 2009) and 
nutritional status ( Schifferle RE, 2005). 
 Studies have shown that short term high fat diets results in prolonged impairment 
of polymorphonuclear leucocytes (Cutler et al, 1999). Thus a hyperlipidaemic state may 
impair the host response to bacterial infections. Elevated serum lipids may directly 
interact with the macrophage cell membrane, interfering with membrane bound-
receptors, enzyme systems and altering macrophage gene expression for essential 
polypeptides,  growth factors and pro-inflammatory cytokines, such as TNF-α and IL-1β 
which are believed to be associated with periodontal disease (Stashenko P et al, 1991, 
Heasman PA et al , 1993).  
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  Obesity on the other hand is a major public health problem . Obesity is a well 
known risk factor for several chronic diseases most notably hypertension, type 2 diabetes, 
dyslipidemia, and coronary heart diseases.(Must et al 1999, Mokdad et al 2004, Fleagel 
et al 2006, Greg et al 2005). In fact, the adipose tissue secretes several cytokines and 
hormones collectively called adipokines (Kershaw and Flier et al 2004) involved in the 
inflammatory process, suggesting that similar pathways are involved in the 
pathophysiology of obesity and periodontitis.  
Predominant cytokines secreted by adipocytes include TNF-α and IL-6 which are 
the main inducers of acute phase proteins such as the CRP (Yudkin et al 2000) which 
may be associated in the development of cardiovascular diseases (American Heart 
Association,2000). Similarly periodontal pathogens affect local and systemic immune 
and inflammatory responses which may initiate systemic acute- phase response that in 
turn may (Baumann H, Gauldi J, 1994)  lead to the production of inflammatory markers 
such as CRP and serum amyloid A protein. 
 Recent investigations suggested that even a moderate increase in CRP levels, 
such as those found in periodontitis patients, may predict a risk for atherosclerosis and 
CVD (Tracy RP, LemaitreRN,et al, 1997, Haverkate F, Thompson S,et al 1997, 
Ridker PM, Cushman M, et al 1998, Lagrand, et al 1999) .This study is aimed to 
evaluate whether obesity , blood cholesterol levels and high-sensitive C reactive protein 
has influence over the periodontal status and thereby to assess if  obesity could be one 
among the potential  risk factors for the pathogenesis of periodontal diseases. 
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              AIM AND OBJECTIVES 
The aim of the present study was to determine whether obesity, which is 
associated with the development of number of chronic diseases, acts as a contributing 
factor in the development or progression of periodontal disease.   
 
For this purpose, the following objectives were undertaken 
     1. To evaluate the relationship between central obesity, blood cholesterol, hsCRP 
levels and periodontal disease. 
    2. To assess whether obesity is an independent risk indicator for periodontal diseases. 
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REVIEW OF LITERATURE 
 
DEFINITION AND ASSESSMENT OF OBESITY: 
 
The definition of obesity is based on the body mass index (BMI, also called 
Quetelet Index), which is the ratio of body weight (in kg) to body height (in m) squared 
(Claude Lenfant et al,Expert Panel, 1998, National institute of health).  
BMI is highly correlated with fat mass and morbidity and mortality, and therefore 
sufficiently reflects obesity-related disease risk in a wide range of populations; however, 
there are some limitations. For example, for the same BMI, older persons tend to have a 
higher body fat composition. Furthermore, current BMI cut-off points for overweight and 
obesity are probably too high for Asian populations (Choo et al, 2002). More 
importantly, the BMI does not assess body fat distribution. It is well-known that 
abdominal (central, visceral, android) obesity, which is usually observed in men, is 
associated with a higher morbidity than the gluteofemoral (peripheral, gynoid) obesity 
typically observed in women (Claude Lenfant et al, Expert Panel, 1998, National 
institute of health). 
 Body fat distribution is assessed by the measurement of waist circumference, 
with 102 cm in men and 88 cm in women, respectively, being the cut-off point for 
abdominal obesity associated with an increased risk of morbidity (Claude Lenfant et 
al,Expert Panel, 1998, National institute of health). Waist circumference shows a close 
correlation with the amount of visceral adipose tissue, and visceral adipose tissue has 
been shown to be metabolically more active and secrete far greater amounts of cytokines 
 
 
5 
 
and hormones compared with subcutaneous adipose tissue (Pouliot et al., 1994; 
Wajchenberg, 2000; Berg and Scherer, 2005). Furthermore, a higher influx of portal 
fatty acids, cytokines, and hormones into the liver from omental adipose tissue may 
specifically distort hepatic metabolism, including abnormal lipoprotein synthesis, hepatic 
insulin resistance, and increased gluconeogenesis (Eckel et al., 2005; Haslam and 
James, 2005). Recently, large studies have indicated that measurement of waist 
circumference or waist-hip ratio may be a better disease risk predictor than BMI (Wang 
et al., 2005; Yusuf et al., 2005). 
  
Classification and Definition of Overweight and Obesity established for non-Asian 
populations (based on Expert Panel, 1998, National institute of health) 
 
Classification               BMI (kg/m2)              
Underweight                < 18.5  
Normal                         18.5-24.9  
Overweight             25.0-29.9                                                                                        
Obese - Class I             30.0-34.9                                    
Obese - Class II            35.0-39.9                                    
Obese - Class III           > 40                                          
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 The recently proposed classification for Asian populations is:  
(WHO/IASO/IOTF, 2000) 
 
BMI  < 18.5       => underweight; 
          18.5-22.9   =>  normal weight;  
          23.0-24.9   => overweight;  
          25.0-29.9   => obese class I; 
          > 30.0        => obese class II.     
 
ROLE OF BODY FAT DISTRIBUTION: 
 
A major predictor of health risk associated with obesity is body fat distribution. 
Body fat may be preferentially located in the abdomen (android obesity pattern) or 
surrounding the hips and thighs (gynoid obesity pattern). Numerous studies have 
demonstrated that the android pattern often reflects an accumulation of fat surrounding 
the abdominal visceral organs and is associated with a variety of metabolic 
derangements, including dyslipidemia, hypertension, and glucose intolerance. (Kissebah 
AH et al, 1994). Thus, even at the same level of overweight, the individual with a greater 
amount of visceral fat is more likely to have, or to have developed, many of the serious 
health conditions associated with obesity. Sex (Montague et al, 1997) and ethnicity 
(Stevens J.et al, 1995) have an impact on body fat distribution and adipose tissue 
metabolism. 
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OBESITY-RELATED DISEASES: 
Diseases for Which Sufficient Evidence Exists That Their Risk is Increased by 
Obesity (Clinical guidelines on the identification, evaluation, and treatment of overweight and 
obesity in adults—The evidence report. National Institutes of Health, 1998; Expert Panel, 1998; 
Haslam and James, 2005; Overweight, obesity, and health risk. National Task Force on the 
Prevention and Treatment of Obesity, 2000) 
 
• Type 2 diabetes 
• Hypertension 
• Dyslipidemia 
• Coronary heart disease 
• Stroke 
• Gall bladder disease 
• Liver disease (non-alcoholic steatohepatitis) 
• Musculoskeletal disease (osteoarthritis) 
• Sleep apnoea and pulmonary dysfunction 
• Cancer (colon cancer, endometrial cancer, post-menopausal breast cancer, kidney 
   cancer) 
• Reproductive abnormalities (menstrual irregularities, infertility) 
 
Hypertension  
Overweight and obesity have long been recognized as important determinants of 
elevated blood pressure levels (Must et al., 1999). It is well-established that weight gain 
is consistently associated with increased blood pressure, and that weight loss decreases 
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blood pressure independent of changes in sodium intake. Compared with normal-weight 
individuals, Obese  persons have an upto 5 times higher risk of hypertension, and upto 
2/3 of cases of hypertension can be attributed to excess weight (Wolf et al., 1997). 
Mechanisms that have been implicated in the development of obesity-related 
hypertension include increased sympathetic nerve activity, sodium and volume retention, 
renal abnormalities, insulin resistance, hyperleptinemia, and increased secretion of 
angiotensinogen from adipocytes (Kolanowski, 1999; Haslam and James, 2005). 
 
Type 2 Diabetes: 
The relationship between obesity and type 2 diabetes is particularly close. Obese 
persons have a more than 10-fold increased risk of developing type 2 diabetes compared 
with normal-weight persons (Field et al., 2001). Type 2 diabetes develops due to an 
interaction between insulin resistance and beta cell failure (Stumvoll et al., 2005). 
Several factors, including lipotoxicity and glucose toxicity as well as obesity derived 
cytokines, have been implicated in these processes (Stumvoll et al., 2005). 
 
Cardiovascular Disease and the Metabolic Syndrome: 
Obese persons have an about 1.5-fold increased risk for cardiovascular disease 
(including coronary heart disease and cerebrovascular disease), and between 10 and 15% 
of all cases of cardiovascular disease can be attributed to overweight and obesity (Wilson 
et al., 2002).  
The association with obesity is slightly stronger, and the population-attributable 
fraction (PAF, i.e., the fraction of cases within the population that can be attributed to 
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overweight and obesity) is larger, for coronary heart disease (relative risk about 1.5 to 
2.0; PAF 15 to 20%) than for cerebrovascular disease (RR 1.2 to 1.8; PAF 5 to 15%) 
(Field et al., 2001; Wilson et al., 2002). 
 Obesity is also associated with an about two-fold higher risk of heart failure and 
a 50% increased risk of atrial fibrillation (Kenchaiah et al., 2002).  
The metabolic syndrome is a concept that encompasses metabolic abnormalities 
that co-occur to a greater degree than would be expected by chance alone, and which 
predispose individuals for a higher risk to develop cardiovascular disease (Eckel et al., 
2005). 
The metabolic syndrome is associated with components, namely, glucose 
intolerance, obesity, hypertension, and dyslipidemia (albeit the WHO also includes 
microalbuminuria as a component) (WHO, 1999; International Diabetes Federation, 
2005). To date, most studies have used the definition provided in the "Third Report of 
the National Cholesterol Education Program, Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III) (NCEP-ATPIII)", which requires the presence of at least three of the 
following metabolic abnormalities before the metabolic syndrome can be defined: 
abdominal obesity, elevated triglycerides, reduced levels of HDL cholesterol, high 
blood pressure, and high fasting glucose. 
Although the exact underlying cause of the metabolic syndrome is unknown, the 
more recent definitions emphasize the focus on abdominal obesity as its core component 
(International Diabetes Federation, 2005). This approach is supported by a growing 
number of studies showing that the adipose tissue itself is capable of producing several 
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hormones and proteins, which are involved in the development of obesity related 
diseases.  
 
Sleep Apnea and Pulmonary Dysfunction: 
 
Sleep apnea is defined as a cessation of airflow during sleep for atleast 10 
seconds, which can be central,obstructive , or mixed .Obesity is a major correlate with 
sleep apnea in men and women, among those having a BMI of at least 30 who are at 
greatest risk (Strohl KP et al ,1998). Obesity is believed to change upper-airway 
geometry through loading of the wall of the pharynx or through increased deposition of 
periluminal fat . There are fairly well-established data indicating that symptoms of sleep 
apnea improve with weight loss. (Strohl KP et al ,1998). 
 
Stroke: 
Overweight may increase the risk for ischemic, but not hemorrhagic stroke. In the 
Nurses’ Health Study, (Rexrode KM et al, 1997) ischemic stroke risk was 75% higher in 
women with a BMI of greater than 27 and 137% higher in those with a BMI of greater 
than 32 
 
Gallbladder Disease: 
 
The risk for gallstones and cholecystectomy increases with increasing body 
weight (Khare M et al 1995) 
 
 
 
 
 
11 
 
Liver Disease: 
 
Nonalcoholic steatohepatitis (NASH) is a pathologic condition with all of the 
features of fatty infiltration, inflammation, and fibrosis seen in alcoholic liver disease, but 
occurring in the absence of excessive alcohol intake (Sheth SG et al, 1997). It is more 
common in persons with obesity and with type 2 diabetes mellitus. 
 
 
ASSOCIATION BETWEEN OBESITY AND PERIODONTAL 
DISEASE: 
 
 
It has been suggested that obesity is second only to smoking as the strongest risk 
factor for inflammatory periodontal tissue destruction (Nishida et al., 2005). The first 
report on the relationship between obesity and periodontal disease appeared in 1977, 
when Perlstein et al. observed histopathologic changes in the periodontium in hereditary 
obese Zucker rats (Zucker and Zucker, 1962; Perlstein and Bissada, 1977). Using 
ligature-induced periodontitis, they found alveolar bone resorption to be greater in obese 
animals compared with non-obese rats (Perlstein and Bissada, 1977). 
 Also, it seemed that, under healthy oral conditions, obesity per se does not 
promote pathologic periodontal alterations; however, in response to bacterial plaque 
accumulation, periodontal inflammation and destruction were more severe in obese 
animals. In obese and hypertensive rats, plaque accumulation caused even more 
pronounced periodontal destruction than in obese animals, suggesting that a combination 
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of risk factors, such as those defined by the metabolic syndrome, elicit the most severe 
periodontal effects (Koletsky, 1973; Perlstein and Bissada, 1977). 
 Saito et al analyzed 241 healthy Japanese individuals and showed, for the first 
time, an association between obesity and periodontal disease in humans (Saito et al., 
1998). They applied the community periodontal index of treatment needs (CPITN) and 
estimated, based on their cross-sectional analysis, that the relative risk for periodontitis 
after adjustment for confounders such as age, gender, oral-hygiene status, and smoking 
was 3.4 in persons with BMI of 25 to 29.9 kg/m
2
, and 8.6 in those with BMI above 30 
kg/m
2
.  
In addition, studies have indicated that the fat distribution pattern plays a crucial 
role in the association with periodontitis (Saito et al., 2001; Al-Zahrani et al., 2003; 
Wood et al., 2003). Saito et al. found, in 643 healthy Japanese adults, that high upper 
body obesity and high total body fat were correlated with a higher risk of periodontal 
disease, compared with normal-weight persons (Saito et al., 2001).  
An examination of the NHANES III data demonstrated that waist-to-hip ratio, 
BMI, fat-free mass, and log sum of subcutaneous fat significantly correlated with 
periodontal disease (Wood et al., 2003).  
Also, high waist circumference was especially associated with periodontal disease 
in 18- to 34-year-old persons, but not in older adults, suggesting a closer correlation 
between high waist circumference and periodontitis in young adults (Al-Zahrani et al., 
2003).  
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In 706 South Brazilian individuals, no correlation between BMI and periodontal 
disease was found in men, but a strong correlation was found in obese females (Dalla 
Vecchia et al., 2005).  
Another recent study by Saito et al. concluded that obesity is associated with deep 
periodontal pockets, independent of glucose tolerance status (Saito et al., 2005). 
 Genco et al. analyzed NHANES III data and demonstrated that BMI was 
positively correlated with the severity of periodontal attachment loss; they found that this 
relationship is modulated by insulin resistance (Genco et al., 2005).  
Recent studies have indicated that maintaining a normal weight by regular 
physical activity is associated with a lower periodontitis prevalence (Wakai et al., 1999; 
Karjalainen et al., 2002; Merchant et al., 2003; Al-Zahrani et al., 2005a,b). 
 Individuals who pursued regular exercise have lower plasma levels of 
inflammatory markers, such as IL-6 and C-reactive protein (CRP), and show an increased 
insulin sensitivity that may beneficially affect periodontal health (Merchant et al., 2003; 
Pischon et al., 2003; Al-Zahrani et al., 2005a).  
A study that analyzed the NHANES III study population demonstrated that 
individuals who maintained a normal weight, pursued regular exercise, and consumed a 
diet in conformity with the Dietary Guidelines for Americans and the Food Guide 
Pyramid recommendations were 40% less likely to have periodontitis (Al-Zahrani et al., 
2005).  
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ASSOCIATION OF PERIODONTITIS WITH OBESITY-RELATED 
CHRONIC DISEASES: 
 
 
 
 
Pro-inflammatory cytokines may play a crucial role in the close relationship 
among periodontitis, obesity, and chronic diseases (Beck and Offenbacher, 2005; 
Genco et al., 2005). In fact, this association may be multidirectional. For example, it has 
been well-established that inflammation is an essential component in the development of 
atherosclerosis, and observational  studies showed that periodontitis is associated with a 
moderately, but significantly, higher risk of coronary heart disease (Beck and 
Offenbacher, 2005; Dietrich and Garcia, 2005; Mattila et al., 2005).  
Inflammatory diseases like periodontitis induce the production of pro-
inflammatory cytokines such as TNF-α, IL-1, and IL-6 (Beck et al., 1996; Loos, 2005). 
It has been suggested that the secretion of TNF-α by adipose tissue triggered by LPS 
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from periodontal Gram negative bacteria promotes hepatic dyslipidemia and decreases 
insulin sensitivity (Saito et al., 2001; Nishimura et al., 2003). 
Type 2 diabetes and decreased insulin sensitivity are associated with the 
production of advanced glycation end-products (AGE), which trigger inflammatory 
cytokine production, thus predisposing for inflammatory diseases such as periodontitis 
(Grossi and Genco, 1998; Genco et al., 2005). These observations suggest a potential 
interaction among obesity, periodontitis, and chronic disease incidence, although present 
studies are insufficient to conclude whether such associations are causal. Thus, in 
addition to being a risk factor for type 2 diabetes and coronary heart disease, obesity-
related inflammation may also promote periodontitis. Conversely, periodontitis, once it 
exists, may promote systemic inflammation and thereby increase the risk of coronary 
heart disease (Beck and Offenbacher, 2005; Loos, 2005). In this context, it is interesting 
to note that periodontal treatment has been shown to reduce circulating TNF-α and serum 
levels of glycosylated hemoglobin, and has beneficial effects on the control of type 2 
diabetes (Grossi and Genco, 1998). 
 
Adipose-tissue-derived hormones and cytokines (adipokines): 
The traditional view of adipose tissue as a passive reservoir for energy storage is 
no longer valid. Adipose tissue is now known to express and secrete a variety of bioactive 
peptides, known as adipokines, which act at both the local (autocrine/paracrine) and 
systemic (endocrine) level. It is now clear that adipose tissue is a complex and highly 
active metabolic and endocrine organ. In addition to adipocytes, adipose tissue contains 
fibroblasts, preadipocytes, tissue resident macrophages, and vascular constituents. 
Macrophages are known to be crucial contributors to inflammation, but more recently, it 
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has been recognized that adipocytes demonstrate significant intrinsic inflammatory 
properties as well. Like macrophages, the adipocyte is exquisitely sensitive to infectious 
disease agents and cytokine-mediated inflammatory signals; it expresses a host of 
receptors, enabling it to sense the presence of pathogens and inflammation, and on 
stimulation of these receptors, it activates multiple inflammatory signal transduction 
cascades, that induces and secretes a number of potent inflammatory cytokines and acute 
phase reactant proteins. 
The underlying biological mechanisms for the association of obesity with 
periodontitis are not well-known; however, adipose-tissue-derived cytokines and 
hormones may play a key role. Fat tissue is not merely a passive triglyceride reservoir of 
the body, but also produces a vast amount of cytokines and hormones, collectively called 
adipokines or adipocytokines (Kershaw and Flier, et al 2004), which in turn may 
modulate periodontitis.  
Adipose tissue secretes pro-inflammatory cytokines such as tumor necrosis factor-
alpha (TNF-α) and interleukin-6 (IL-6). TNF-α and IL-6 are the main inducers of acute-
phase hepatic protein production, including C-reactive protein (CRP) (Yudkin et al., 
2000).  
Both TNF-α and IL-6 have been shown to impair intracellular insulin signaling, 
which may lead to insulin resistance (Hotamisligil, 2000; Rotter et al., 2003). In 
humans, plasma levels of TNF-α, IL-6, and CRP are closely related to obesity and insulin 
resistance (Hotamisligil, 1999; Kern et al., 2001).  
There is compelling evidence that inflammation plays an essential role in the 
development of type 2 diabetes mellitus and atherosclerosis, and studies in humans 
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suggest that circulating inflammatory marker levels may predict type 2 diabetes and 
cardiovascular events years in advance of the onset of these diseases (Pradhan et al., 
2001; Libby, 2002; Pradhan and Ridker, 2002; Ridker, 2002; Danesh et al., 2004; 
Pai et al., 2004).  
An up to 10-fold increase in local and systemic expression of inflammatory 
cytokines, such as TNF-α and IL-6, by monocytes and macrophages has been reported in 
some individuals with periodontitis (Beck et al., 1996).  
In persons with periodontitis, bacterial pathogens, endotoxins, and inflammatory 
cytokines may systemically trigger an up-regulated leukocytosis, synthesis of acute-phase 
proteins (CRP, Amyloid A), and enhanced lipid metabolism, along with increased serum 
cholesterol and triglyceride levels, which may contribute to the risk of systemic diseases 
such as cardiovascular diseases (Beck et al., 1998; Loos et al., 1998; Nishimura et al., 
2003; Beck and Offenbacher, 2005; Loos, 2005; Mattila et al., 2005).  
 
Acute –phase proteins: 
It has been long established that immune mediators originating from a site of 
infection or from a site of severe trauma may activate hepatocytes in the liver to produce 
large quantities of Acute –phase proteins (Steel et al, 1994). The acute-phase response is 
characterized by fever, increased vascular permeability, and a general elevation of 
metabolic processes. These acute-phase reactants posses a wide variety of functions. 
These include pro-inflammatory properties, activation of complement factors, 
neutralization of invasive pathogens, stimulation of repair and regeneration of variety of 
tissues (Steel et al, 1994). The acute –phase proteins receiving most attention includes C-
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reactive protein (CRP), serum amyloid P component, serum amyloid A protein and α 1 –
acid glycoproteins (AGP).  
  
C-Reactive Protein: 
C-reactive protein (CRP) is an acute-phase reactant produced by the liver in 
response to diverse inflammatory stimuli, including heat, trauma, infection, and hypoxia 
(Pepys and Baltz, 1983). In patients with overwhelming systemic infection, serum levels 
of CRP can exceed 100 mg/L, providing a useful marker for tracking the course of the 
infection.  
Historically, CRP values of > 10mg/l have been regarded as diagnostic for a 
bacterial infection, while values <10mg/l have been neglected (also because one was 
unable to measure CRP accurately <10mg/l). in the mid 1990s, hi-sensitivity assays for 
CRP came into widespread use, allowing laboratories to determine CRP levels as low as 
0.3 mg/l. 
However, the clinical relevance of much smaller increases in CRP has been 
highlighted recently in epidemiological studies demonstrating that individuals with "high-
normal" values of CRP have increased risks for chronic diseases that have an 
inflammatory basis, including cardiovascular disease. Established risk factors for "high-
normal" values of CRP within the general population include older age, cigarette 
smoking, chronic bacterial infections, and chronic bronchial inflammation (Palosuo et 
al., 1986; Saikku et al., 1992; Patel et al., 1995; Mendall et al., 1996; Ridker et al., 
1997). 
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CRP has been shown to play a role in the pathogenesis of atherosclerosis through 
different mechanisms including binding the phosphocholine of oxidized low density 
lipoproteins, upregulating the expression of adhesion molecules in endothelial cells, 
increasing low density lipoprotein uptake in to macrophages, inhibiting endothelial nitric 
oxide synthase expression in aortic endothelial cells and increasing plasminogen activator 
inhibitor – 1 expression and activity. (Black, Kushner et al 2004). 
  The first observations of the well-known association between CRP and cardiac 
risk was in 1954,when it was found that after myocardial infarction, there was a dramatic 
rise in circulating CRP levels and the amplitude of this rise correlated with poor 
prognosis. (Kroop IG, Shackman NH. 1954,  Anzai T, Yoshikawa T, Shiraki H). 
  Subsequently, it was also found that pre-infarct elevated CRP levels correlated 
with an increased risk of future cardiac events as well. Not only were pre-infarction CRP 
levels correlated with increased risk for later adverse cardiac events and sudden death, 
elevated circulating levels of IL-6, IL-18, levels have been correlated recently with 
increased risk of congestive heart failure development in elderly patients even before 
evidence of CVD. (Vasan RS, Sullivan, 2003). 
Numerous additional studies have further strengthened the association of elevated 
CRP levels with nearly all the important cardiovascular risk factors, including insulin 
resistance and diabetes, metabolic syndrome, hypertension, smoking, and dyslipidemia 
(Saito M, Ishimitsu T, 2003). Elevated CRP levels in obese patients are not only 
prognostic for the development of CVD but also predictive of the risk of progression to 
type 2 diabetes mellitus. (Pradhan AD, Manson JE, 2001).  
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Elevated CRP levels in obesity and the decrease in its levels associated with 
weight loss provide another suggestive link between CRP and obesity-associated risks for 
CVD and diabetes. (Heilbronn LK, Noakes, 2001; Kopp HP, Kopp CW, Festa A, 
2003; Tchernof A, Nolan A, 2003;  Esposito K, Pontillo A, 2003). 
 
 PERIODONTAL DISEASE AND CRP: 
 An ever-increasing number of reports  have demonstrated  CRP in relation to 
periodontitis. 
 Ebersole et al, 1996 
 
observed relatively high levels of CRP: 9 mg/1 in study 
group versus 2 mg/1 in controls. 
Hujoel et al, 2001  reported a median CRP of 2 mg/1 was observed for peri-
odontitis patients, while the median among controls was 0 mg/l. 
Loos et al, concluded that the highest CRP values were found in patients with a 
generalized form of periodontitis (median 1.45 mg/1); for patients with a more localized 
form of periodontal disease, the median CRP value was 1.30 mg/1, while healthy controls 
presented with a median of 0.90 mg/1 .This demonstrates that CRP also behaves in a 
dose-dependent manner. 
Epidemiological studies from Buffalo, New York, reported elevated CRP in 
blood plasma among subjects with severe periodontal attachment loss in comparison to 
individuals with minimal to no attachment loss (Noack, Genco et al, 2001, Glurich, 
Grossi et al, 2002). These studies also reported that those subjects who were infected 
with periodontal pathogens had clearly higher levels of CRP than those who were not 
harboring them. 
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Buhlin et al 2003 observed higher plasma levels of CRP   in severe periodontitis 
patients in comparison to healthy controls.  
Recently elevated CRP concentrations were found among periodontal patients in 
New York City of Hispanic, Asian, or African American background. In this study by 
Craig et al, 2003, a dose response effect of CRP was found: the numbers of periodontal 
lesions were positively correlated to CRP values. 
Cross-sectional epidemiological surveys in Japan revealed that individuals with 
the highest CPITN or community periodontal index (CPI) scores had higher CRP values 
than those with lower CPITN or CPI scores. (Wakai et al 1999, Takami et al, 2003). 
 In another Japanese study among men only, a strong positive correlationwas 
found between alveolar bone loss and plasma CRP level. (Saito et al, 2003). 
In a cross-sectional epidemiological survey in the United states, Slade et al, 2000 
observed CRP values of 4.5 mg/l for subjects with >10%  pockets of  >4 mm in depth in 
contrast to those subjects without pockets  >4 mm, who had an of average 3.3 mg/l CRP. 
Some intervention studies have investigated the effects of periodontal therapy on 
CRP levels.
 
Mattila et al (2004) reported a reduction of CRP concentrations on 30 
patients with chronic periodontitis; the median value at baseline was reduced from 1.05 
mg/1 to 0.7 mg/1 after therapy. This reduction of CRP levels was most clearly observed 
among those who had CRP values >2 mg/1 before therapy.  
Recently, a large pilot intervention study among periodontitis patients was 
reported in which 94 patients with severe periodontitis received non-surgical therapy. At 
6 months after treatment, the median value for CRP was reduced by 0.5 mg/1 (1.9 mg/1 
at baseline and 1.4 mg/1 6 months after basic periodontal therapy). Interestingly, two 
 
 
22 
 
months after therapy, the reduction in CRP was not yet observed, (Daiuto et al, 2004) 
suggesting a slow healing process in these subjects with severe periodontitis. Similar 
observations were made by Ide et al ( 2004) while Mattila et al.(2004)
 
observed their 
results only 6 weeks postoperatively. Further intervention studies are needed to 
completely understand the dynamics of CRP in relation to periodontal therapy. 
 
PERIODONTITIS AND HYPERLIPIDEMIA: 
Animal studies have demonstrated a causal relationship between hyperlipidemia 
and periodontitis. Investigations in rats by Ueno et al in 1965
 
have demonstrated that 
animals placed on high fat diet developed periodontitis. 
 The study of Feingold et al 1992
 
showed that the administration of low doses of 
endotoxins in rats resulted in hypertriglyceridemia suggesting the presence of a similar 
response in local infections such as periodontal disease. 
 The study of Memon et al 1993
 
has proved that induction of periodontitis by 
P.gingivalis in rats resulted in increased level of TGL. Using similar methodology, the 
same result was observed in work of Doxey et al in 1998. 
 Studies in non human primates by Ebersole et al in 1999
 
have demonstrated 
elevations in serum lipids of inflammatory biomarkers and LDL/TG during gingivitis and 
periodontitis. Additionally these changes were exacerbated by high fat diet and animals 
on high fat diet exhibited more severe periodontitis.  
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 Human studies appear to confirm the hyperlipidemia - periodontitis relationship. 
Subjects with hyperlipidemia demonstrated significantly more severe periodontitis than 
community based controls and the degree of periodontal breakdown was positively 
correlated to plasma lipid levels. (Pohl et al 1995).  A study measuring serum lipid levels 
in systemically healthy patients with moderate periodontitis by Netea et al in 1997
 
showed a significant elevation of serum LDL/TG in periodontitis patients compared to 
controls. 
 Studies involving clinical evaluation/laboratory assessment of healthy and 
diabetic patients suggest a potential linkage between periodontitis, elevated serum lipid 
and level of bacteremia. (Cutler et al 1999)
 
. Analysis of sera from random healthy clinic 
patients demonstrated significant elevations of serum lipids and P.gingivalis titers in 
patients with periodontitis compared to patients without periodontitis. It also 
demonstrated significant association between the presence of disease with total serum 
cholesterol, TG and amount of P.gingivalis antibodies. (Cutler et al 1999). 
 According to National Cholesterol Education Program periodontal disease was 
more prevalent in subjects with a serum HDL-C concentration <60mg/dl suggesting that 
periodontal disease is exacerbated by metabolic syndrome.( NCEP 2000). 
 Losche et al in 2000
 
showed that the plasmatic level of lipids in periodontitis 
patients were significantly higher than the healthy individuals. 
 Noack et al in 2000 studied 100 subjects and suggested that hyperlipidemia is a 
risk factor for periodontal disease, while impaired glucose tolerance is not. 
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 In 2002, Katz et al evaluated the periodontal health of over 10000 Israeli military 
service men and women and compared the results with their blood lipid levels and did not 
find a significant association between the presence of periodontal pockets and high levels 
of triglycerides. While some authors like Katz et al 2001, 2002 mentioned that there 
were significant correlations between periodontal status and cholesterol levels, whereas 
Cutler et al 1999, Morita et al 2004 , indicate that there were significant association 
between trigyceride level and periodontal disease. 
After periodontal treatment, significant increase in serum HDL-C concentration, 
HDL2/HDL3 and HDL phospholipids content were observed. In this study, Pussinen et 
al 2004
 
stated that periodontitis decreases the antiatherogenic potency of HDL. 
A study by Aki Izumi et al on 2009 showed that higher total cholesterol is 
associated with lower prevalence of periodontitis in non smoking elderly patients. 
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      MATERIALS  AND METHODS 
 
STUDY  DESIGN  AND  SUBJECT SELECTION: 
 
The   study was   approved by the Institutional Ethical committee. 100  patients  in  
the  age   group  of  18- 59  years who  attended  the  out  patient department , 
Department of Periodontics, Tamil Nadu Government Dental College, Chennai  between  
June  and  October 2010  participated  in the  study . 
The study population was categorized into two groups based on their age; the 
younger age group comprising 50 subjects between the ages 18-34, and the middle aged 
group comprising 50 subjects between the ages 35-59. Patients more than 59 years were 
not included in the study due to the expected presence of many confounding factors, 
extreme age being one of it and the presence of many systemic illnesses. These two 
groups were designated as Group I and Group II respectively. 
Subjects within these two groups were further sub-divided into 2 subgroups 
depending on their body mass indices. One subgroup comprised of 25 subjects each. The 
BMI cut off decided to categorize the subjects was 22.9 which is accordance to the 
guidelines endorsed by the INDIAN DIABETIC ASSOCIATION for the Indian 
population who are at increased risk for developing overweight/obesity related 
complications compared to their western counterparts. Hence one subgroup consisted of 
subjects having BMI 22.9 or less and the other subgroup comprised of subjects with BMI 
23 or more. 
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Similarly the 2
nd
 group comprising of age range 35-59 years was also divided in 
the same way into 2 subgroups. Both males and females participated in the study 
irrespective of gender. 
To summarize, the subjects were divided in the following way 
GROUP I: Age range from 18-34 years 
GroupIa: subjects having BMI 22.9 or less 
GroupIb: subjects having BMI 23 or more 
GROUPII: Age range from 34-59 years 
GroupIIa: subjects having BMI 22.9 or less 
GroupIIb: subjects having BMI 23 or more 
A   written informed consent was obtained from all   patients.    A complete   
history  and  clinical  features  of  the  subjects    attending study  were obtained. Prior  to  
blood  sample  collection , plaque  index, bleeding index, probing  depth,  clinical  
attachment  loss  were  recorded. 
 5 ml of fasting venous blood samples were collected from the patients for the 
estimation of lipid profile and CRP levels. 
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INCLUSION CRITERIA:        
1.  Patients willing for voluntary participation and having signed the informed 
consent. 
2. Age : 18-59 years  
3. Gender : Both males and females 
4. Patients with minimum 20 teeth. 
   
 EXCLUSION CRITERIA: 
1.  Trauma or tooth extraction within 2 weeks 
2.  Patients drug history (anticholesterol drugs, antibiotics, anticoagulants) for 
past 2 months.                                 
            3.  Any chronic   infectious diseases. 
            4.   Pregnancy  
            5.  Anemia, bleeding disorders or any other hematological disorder  
            6.  Cardiac or respiratory diseases  
            7.  Stroke or diabetes 
            8.  Smoking habits, pan chewing, alcoholism 
            9.  Malnourished or underweight patients. 
          10.  History of periodontal treatment 6 months prior to study. 
 
STUDY PROTOCOL: 
1  Institutional  ethical  committee  approval   
2.  Medical History and Informed Consent 
3. Periodontal Examination using clinical parameters namely, Bleeding Index, 
Plaque Index, Probing Pocket Depth and Clinical Attachment Level. 
4. Measurement of body mass index and waist hip ratio 
5. Collection  of blood samples 
6.  Estimation   of  serum blood lipid profile and HsCRP. 
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      Following selection of subjects, written informed consent was obtained from all 
the subjects selected for the study after explaining the study procedure. Examination was 
preceded by a thorough medical and dental history of the subjects. Intra-oral examination 
was done using mouth mirror and William’s Periodontal Probe. Periodontal Evaluation 
was done by measuring the Bleeding Index, Plaque Index, Probing Pocket Depth (PPD) 
and Clinical Attachment Level (CAL). 
ARMAMENTARIUM: 
For examination: 
Mouth mirror 
William’s  periodontal  probe 
Gloves and  mask 
Sample collection: 
5ml syringe  
Spirit 
Sterile cotton 
To measure general parameters: 
Weighing machine 
Height indicator  
Measuring tape 
Reagents/ Consumables: 
SYNCHRON CX MULTI Calibrator 
CHOL Reagent Cartridges 
SYNCHRON CX9 PRO TG Reagent Cartridges 
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Sekisui HDL Reagent 
SYNCHRON CX reagent cartridges 
Sekisui Cholestest Calibrator 
Sekisui LDL Reagent 
Cuvettes & Tips 
Equipment:  
Synchron CX9 PRO Clinical Chemistry Analyzer 
 
General Examination: 
 
Waist-hip Ratio: 
 
Subjects' waists and hips were measured.  Upper body obesity is defined as a 
waist-hip ratio of ≥0.8 for females and ≥0.9 for males. These differences were derived 
from skeletal differences and differences in fat distribution between sexes. The difference 
was 0.12 between the sexes and was almost the same in any age categories.  
Measurement of W: H ratio: 
A measuring tape was used to measure the waist and hips. Waist 
measurement was done at the region of the umbilicus and the hips are measured at 
its widest position. 
Normal W: H Ratio 
Females <0.8 
Males <0.9 
 Height measurement: Height was measured using a height indicator in cms. 
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Weight measurement: measured using weighing machine in kgs. 
BMI:    weight in kg 
          Height in meter 
2
 
CLINICAL PARAMETERS: 
 GINGIVAL BLEEDING INDEX (Ainamo & Bay 1975): 
Teeth examined - All teeth 
Surfaces examined - 4 sites for each tooth (Mesial, buccal, Distal, lingual,)  
The presence or absence of bleeding is determined by gentle probing of the gingival 
crevice with a periodontal probe. 
Criteria for Scoring: 
Positive score (+) - Presence of bleeding within 10 seconds  
Negative score (-) - Absence of bleeding 
    Total number of positive score 
% of bleeding sites =            x 100 
    Total number of surfaces of all teeth 
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PLAQUE INDEX (Silness and Loe 1964):
 
  
Teeth examined – All teeth 
Surfaces examined – 4 sites for each tooth (disto-facial, Facial, Mesio-facial, 
lingual/palatal)  
Criteria for Scoring: 
Score 0 - No plaque 
Score 1 - Plaque not visible to the naked eye, detected by explorer 
Score 2 - Thin to moderate accumulation of soft deposits within the gingival pocket 
or on tooth, visible to the naked eye 
Score 3 - Abundance of soft matter within gingival pocket or on tooth surface and 
margin, inter-dental area stuffed with soft debris 
 
Calculation :  
Plaque  index  for  a  tooth= total  score  from  4  areas/4 
Plaque index for the individual = Total Plaque indices for all teeth / No. of teeth 
examined.                                
Interpretation:   Score   0 – Excellent oral hygiene 
                             0.1 to 0.9 – Good oral hygiene 
                             1.0 to 1.9 – Fair oral hygiene 
                             2.0 to 3.0 - Poor oral hygiene 
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PROBING POCKET DEPTH (PPD) (Grant 1965): 
Probing Pocket Depth was measured from the gingival margin to the base of the 
pocket using William’s Periodontal Probe. The probe was passed within the gingival 
sulcus along the circumference of the tooth.  
Three measurements were made on the buccal aspect and three on the lingual 
aspect of each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, Distobuccal, 
Mesiolingual, Midlingual, Distolingual). 
 
CLINICAL ATTACHMENT LEVEL (CAL) ( Carranza): 
Clinical Attachment Level was measured from the Cemento – Enamel Junction (CEJ) 
to the base of the pocket using William’s Periodontal Probe.  
 When the gingival margin was located on the anatomic crown, the level of the 
attachment was determined by subtracting from the probing pocket depth, the 
distance from the gingival margin to the CEJ. If both were the same, the loss of 
attachment was calculated to be zero.  
 When the gingival margin coincided with the CEJ, the loss of attachment was 
calculated as equaling the probing pocket depth.  
 When the gingival margin was located apical to the CEJ, the loss of attachment 
was greater than the probing pocket depth and therefore the distance between the 
CEJ and the gingival margin were added to the PPD. 
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Three measurements were made on the buccal aspect and three on the lingual aspect of 
each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, Distobuccal, 
Mesiolingual, Midlingual, and Distolingual). 
 
ESTIMATION OF C-REACTIVE PROTEIN (CRP-hs): 
 
LATEX HIGH SENSITIVITY : 
 
PRINCIPLE OF THE METHOD: 
 
Serum C-REACTIVE PROTEIN (CRP) causes agglutination of the latex particles 
coated with anti-human C-REACTIVE PROTEIN. This agglutination of the latex 
particles is proportional to the CRP concentration and was measured by turbidimetry. 
CONTENTS AND COMPOSITION: 
 
A.  Reagent: 1 x 40 mL. Glycine buffer 0.1 mol/L, sodium azide 0.95 g/L, pH 8.6. 
B.  Reagent: 1 x 10 mL. Suspension of latex particles coated with anti-human CRP 
antibodies, sodium azide 0.95 g/L 
S. CRP-hs Standard: For 1 x 5 mL Human serum. C-reactive protein concentration is 
stated on the vial label. 
Human serum used in the preparation of the standard has been tested and found to be negative for the 
presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen However, the standard was 
handled cautiously. 
 
STORAGE 
 
Samples were stored at 2-8°C. 
REAGENT PREPARATION 
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Working Reagent: Reagent B was mixed thoroughly with Reagent A in a vial. This 
mixture is stable for 20 days at 2-8°C.                                    
Smaller Working Reagent volumes was prepared by mixing: 1 ml of Reagent B + 4 mL 
of Reagent A. Reagent B vial was shaken well before pipetting. 
CRP-hs Standard (S): Reconstituted with 5.0 mL of distilled water. Stable for 1 month at 
2-8°C. 
Calibration curve: Dilutions of the CRP-hs Standard was prepared using 9 g/L saline as 
diluent. 
Concentration of the CRP-hs Standard was multiplied by the corresponding factor 
indicated below to obtain the CRP-hs concentration.  
DILUTION 
 
1 2 3 4 5 
CRP-hs Standard(µl) 
Saline(µl) 
10 
70 
20 
60 
40 
40 
60 
20 
80 
- 
Factor 0.125 0.25 0.5 0.75 1.0 
 
ADDITIONAL EQUIPMENT: 
                               
Thermostatic water bath was set at 37°C. 
Analyser or spectrophotometer or photometer  thermostable at 37°Cwas used to read at 
540 ± 20nm. 
SAMPLES: 
Serum collected by standard procedures. CRP in serum stable for 7 days at 2-8'C.  
PROCEDURE: 
1The working reagent and the instrument were brought to 37°C.   
2. The instrument is zeroed with distilled water. 
3. The mix was pipetted into a cuvette: 
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Working Reagent                                                    1.5 ml 
Water (Blank), Standard (S) or Sample                  20 µl 
 
4. The sample was mixed well and the cuvette is immediately inserted into the 
instrument.  
 
5. Recording was done with  the absorbance at 540 nm after 10 seconds (A1) and after 5 
minutes (A2) 
 
Calibration curve: The absorbance difference (A2 – A1) of each point was calculated and 
the values were plotted against CRP-hs concentration in a caliberation curve. CRP-hs 
concentration in the sample were calculated by interpolation of its absorbance (A2-A1) on 
the calibration curve. 
REFERENCE VALUES: 
Normal     < 3mg/l 
Increased  >3mg/l  
 
 
PURPOSE OF ESTIMATING  BLOOD  CHOLESTROL:  
Quantitative estimation of Cholesterol in human serum is done by Cholesterol 
oxidase - peroxidase/ end point method. Cholesterol measurements are used in the 
diagnosis and treatment of hypercholesterolemias, atherosclerotic coronary artery disease. 
Cholesterol measurements are also used in the diagnosis of metabolic disorders involving 
lipids and lipoproteins. Total serum cholesterol concentrations depend on many factors 
including age, gender, diet, physical activity, liver disease, and other metabolic disorders. 
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PURPOSE OF  ESTIMATING  BLOOD TRIGLYCERIDES:  
Quantitative estimation of Triglycerides in human serum by GOP-Trinder End 
point method. Triglyceride measurements are used in the diagnosis and treatment of 
patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid 
metabolism, or various endocrine disorders. 
PURPOSE OF  ESTIMATING HDL: 
 Quantitative estimation of HDL CHOLESTEROL in human serum by Direct 
Homogeneous End point method. HDL cholesterol is inversely related to the risk of 
developing coronary artery disease. A low HDL/ LDL cholesterol ratio is directly related 
to the risk of developing coronary artery disease.  
PURPOSE OF  ESTIMATING  LDL:    
Quantitative estimation of LDL Cholesterol in human serum Direct enzymatic 
assay. Measurement of serum LDL cholesterol is useful in the screening of the lipid 
status of the individual to detect atherosclerotic risks and in monitoring the response to 
lipid lowering measures and also in the diagnosis and classification of hyperlipidemias. 
In This Study Complete Lipid Profile Were Estimated To Assess Its 
Influence Over The Periodontal Status Of The Patients 
 
PRINCIPLE OF ESTIMATING BLOOD  CHOLESTROL:  
CHOL reagent was used to measure cholesterol concentration by a timed- 
endpoint method .In the reaction cholesterol esterase (CE) hydrolyzes cholesterol esters 
to free cholesterol and fatty acids. Free cholesterol is oxidized to cholestene-3-one and 
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hydrogen peroxide by cholesterol oxidase (CO). Peroxidase catalyzes the reaction of 
hydrogen peroxide with 4-aminoantipyrine (4-AAP) and phenol to produce a colored 
quinoneimine product. 
Cholesterol ester              
CE                              
Cholesterol + Fatty Acid 
Cholesterol + 02                co                   cholestene-3-one + H2O2 
2H202 + 4-AAP + Phenol    
              peroxidase                     
Quinoneimine + H20 
 
PRINCIPLE OF ESTIMATING BLOOD  TRIGLYCERIDES:  
GPO reagent was used to measure the triglycerides concentration by a timed 
endpoint method. Triglycerides in the sample are hydrolyzed to glycerol and free fatty 
acids by the action of lipase. A sequence of three coupled enzymatic steps using glycerol 
kinase (GK), glycerophosphate oxidase (GPO), and horseradish peroxidase (HPO) causes 
the oxidative coupling of 3,5-dichloro-2-hydroxybenzenesulfonic acid (DHBS) with 4-
aminoantipyrine to form a red quinoneimine dye. 
a) Triglycerides        
 Lipase
                                 Glycerol + Fatty Acids 
b) Glycerol + ATP  
GK
Mg                   Glycerol-3-phosphate + ADP 
(c) Glycerol-phosphate + 02    
GPO
            Dihydroxyacetone + H202 
(d) 2H202 + 4-Aminoantipyrine + DHBS                    Quinoneimine Dye + HCl+ 2H 0 
 
The SYNCHRON CX® System(s) automatically proportions the appropriate sample 
and reagent volumes into the cuvette. The ratio used was one part sample to 100 parts 
reagent. The system monitors the change in absorbance at 520 nanometers. This change 
in absorbance was directly proportional to the concentration of CHOL and TG in the 
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sample and was used by the System to calculate and express CHOL and TG 
concentration. 
PRINCIPLE OF ESTIMATING HDL:  
This direct HDL Cholesterol method is a homogeneous assay without the need for 
any offline pre-treatment or centrifugation steps. The method depends on a unique 
detergent which solubilizes only the HDL lipoprotein particles and releases HDL 
cholesterol to react with cholesterol esterase and cholesterol oxidase in the presence of 
chromogens, to produce a color product. The same detergent also inhibits the reaction of 
the cholesterol enzymes with LDL, VLDL, and chylomicrons lipoproteins by adsorbing 
to their surfaces. A polyanion contained in the reagent enhances the selectivity for HDL 
cholesterol assay by complexing LDL, VLDL, and chylomicrons lipoproteins. HDLD 
reagent is used to measure the cholesterol concentration by a timed-endpoint. 
The  SYNCTRON CX® System(s) automatically proportions the appropriate 
HDL cholesterol reagent and sample volumes into a cuvette. The ratio used was one part 
sample to 93 parts reagent. The System monitors the change in absorbance at 560 
nanometers. This change in absorbance is directly proportional to the concentration of 
cholesterol in the sample and is used by the System to calculate and express the HDL-
cholesterol concentration.                                     
LDL, VLDL, Chylomicrons     
Detergent
           Stable Complexes 
HDL Cholesterol     
Cholesterol Esterase                                 
A
4
 Cholestenone + H?o? 
H?o? + DSBmT + 4-AA                          Color Product 
DSBmT: NN-bis {4-sulphobytyl) - m – toluidine disodium, 4-AA: 4-aminoantipyrine 
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PRINCIPLE OF ESTIMATING LDL: 
 This direct LDL Cholesterol method is a homogeneous assay without the need 
for any offline pretreatment or centrifugation steps. The method depends on a unique 
detergent which solubilizes only the non-LDL lipoprotein particles and releases 
cholesterol to react with cholesterol esterase and cholesterol oxidase to produce a non-
color forming reaction. A second detergent solubilizes the remaining LDL particles, and a 
chromogenic coupler allows for color formation. LDLD reagent is used to measure the 
cholesterol concentration by a timed-endpoint method.  
The SYNCHRON CX   System(s) automatically proportions the appropriate LDL 
cholesterol sample and reagent volumes into a cuvette. The ratio used is one part sample 
to 93 parts reagent. The System monitors the change in absorbance at 560 nanometers. 
This change in absorbance is directly proportional to the concentration of LDL 
cholesterol in the sample and is used by the System to calculate and express the LDL 
cholesterol concentration. 
                                                     Detergent 1              
                                                         
                                                      Cholesterol Esterase       
HDL-C, VLDL-C,CM-C                                                 Non-Color Product
 
                                                                                  Cholesterol Oxidase 
 
 
 Detergent 2    
 
                                                      Cholesterol Esterase       
      LDL Cholesterol                                        ∆ 4 Cholestenone + H2O2 
                                                                                  Cholesterol Oxidase 
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  H202  +  DSBmT  + 4-AA                  
Perioxidase             Color Product                             
 
C = Cholesterol 
DSBmT = N,N-bis (4-sulphobutyl)-m-toluidine-disodium 
4-AA = 4-aminoantipyrine 
 
 
PERFORMANCE SIGNIFICANCE : 
 
For cholesterol: 
Linearity: This assay is linear for concentration up to 750 mg/dL.      
Measurement Range: This method has a measurement range of 5 - 750 mg/dL 
Sensitivity: The analytical sensitivity of this assay is 5 mg/dL.   
For TG: 
Linearity: This assay is linear for concentration up to 1000 mg/dL  
Measurement Range: This method has a measurement range of 10 to 1000 mg/dL 
Sensitivity: The analytical sensitivity of this assay is 10 mg/dL. 
For HDL: 
Linearity: This assay is linear for concentration up to 150 mg/dL.  
Measurement Range: This method has a measurement range of 2to 150 mg/dL. 
Sensitivity: The analytical sensitivity of this assay is 2 mg/dL. 
For LDL: 
Linearity: This assay is linear for concentration up to 450 mg/dL. 
Measurement Range: This method has a measurement range of 1 to 450 mg/dL. 
Sensitivity: The analytical sensitivity of this assay is l mg/dL. 
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 Primary sampling: 
1.  Only serum was used as specimen for the test. 
2.  1.5-2.5 ml of venous blood was collected from a peripheral vein in a yellow topped 
vacutainer tube. Serum was separated within 2 hours of collection. 
3.  The tube was allowed to stand at room temperature till complete clot formation occurs 
(for 30 minutes). It was ensured that complete clot formation has occurred and there are 
no fibrin threads. 
4.  All samples were processed on the same day within 2 hours of collection.  
5. If assay was likely to be done after 48 hours of collection, the serum was stored at - 
20°C. 
6. Hemolysed, contaminated samples were excluded from testing. 
 
Type of Container and additive: yellow topped vacutainer tubes were used. No additive 
or anticoagulants were added 
Calibration Procedure:  
 The system  was calibrated or assayed using the Synchron CX MULTI Calibrator. The 
system has a valid calibration in memory before controls or patient samples were run. 
 The details were recorded in the calibration register. 
 The calibration report was used in conjunction with quality control results to determine 
the validity of calibration 
Step by Step Procedure: 
 The reagent was loaded and then the system is calibrated as required. The reagent status 
was checked  
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The controls were checked before processing patient samples and then the sample were 
ensured to be at room temperature before loading. 
 The vacutainer  was loaded with minimum volume of sample required. 
 
 Reference Interval/ Range:  
CHOLESTEROL 
 Less than 200 mg/dL     - low risk 
 201 to 239 mg/dL          - borderline risk                       
 240 mg/dL and greater  -  high risk 
 
TGL 
CONVENTIONAL UNITS 
Normal                                       Less than 150 mg/dL 
Borderline high                            150-199 mg/d 
High                                           200 - 500 mg 
Very High                                   Greater than 500 mg/dL 
 
HDL 
Serum or Plasma (Male)    :   27 - 67 mg/dL 
Serum or Plasma (Female) : 29 - 89 mg/dL 
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LDL 
   Desirable        : <130mg/dl 
   With high risk: >130 mg/dl 
 
Potential source of variability: 
Presence of fibrin in the sample may lead to erroneous results and hence 
centrifuging the sample was done only after complete clot formation. 
Lysed and contaminated samples can lead to erroneously high values. 
Reagent was thoroughly mixed and packed  gently by  inverting several times before 
loading on to the instrument. 
Haemoglobin, bilirubin, lipemia, ascorbic acid, albumin and urea may affect the 
test results. 
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Photograph 1  :  Armamentarium 
                                     
 
 
Photograph 2: Williams’s periodontal probe used to measure probing pocket depth 
and CAL 
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    Photograph No. 3  Collection of blood sample 
 
        
Photograph no. 4   samples & armamentarium for sample transportation 
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                 Photograph No. 5  SYNCHRON  CX9  PRO CALIBRATOR 
 
            
Photograph No. 6 SEMI- AUTOMATIC  CALIBRATOR 
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   STATISTICAL    ANALYSIS 
The statistical analysis  was  done using  the computer  software  program SPSS  
version 12. 
Mean and Standard Deviation were estimated for different variables in each study group.  
In the present study, P-value <0.05 was considered as the level of significance.   CHI SQUARE 
TEST FOR INDEPENDENCE OF ATTRIBUTES 
 
 
 
 
CORRELATION COEFFICIENT 
 
 
 
 
 
    
 
Where O = Observed frequency in a cell 
           E = Expected frequency in a cell 
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                                          RESULTS 
 
A total of 100  patients  in  the  age   group  of  18- 59  years including males and 
females were selected for the study. The study population was categorized into two 
groups based on their age; the younger age group comprising 50 subjects between the 
ages 18-34, and the middle aged group comprising 50 subjects between the ages 35-
59(Mohammad S. Al-Zahrani et al, 2003 )  
Subjects within these two groups were further sub-divided into 2 subgroups 
depending on their body mass indices. One subgroup comprised of 25 subjects each. The 
BMI cut off decided to categorize the subjects was 22.9 (Ministry of health, India, 
2009). Similarly the 2
nd
 group comprising of age range 35-59 years was also divided in 
the same way into 2 subgroups. Both males and females participated in the study 
irrespective of gender. 
To summarize, the subjects were divided in the following ways 
GROUP I:     Age range from 18-34 years 
Group I a: subjects having BMI 22.9 or less 
Group I b: subjects having BMI 23 or more 
GROUP II:    Age range from 34-59 years 
Group II a: subjects having BMI 22.9 or less 
Group II b: subjects having BMI 23 or more 
Table I shows the mean values of TC, TG, HDL, LDL, HSCRP,WH RATIO, 
BMI, CAL and LDL/HDL ratio among all the groups. The values are  
150.40±22.66, 70.28 ± 30.90, 44.28 ± 11.66, 82.96 ± 25.92, 1.66 ± 1.86, 0.79 ± 
0.05, 20.83 ± 1.71, 0.16 ± 0.41and 1.95 ± 0.69 respectively for group Ia,(table I) 
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164.96 ± 34.33, 97.84 ± 58.11, 36.13 ± 11.31, 77.67 ± 36.02, 5.36 ± 4.45, 0.9 ± 
0.11, 30.97 ± 6.14, 1.29 ± 1.62 and 2.2 ± 0.99 respectively in group Ib, (table I) 
  184± 32.38, 101.16 ± 43.9, 42.31 ± 13.45, 101.52 ± 36.28, 2.18 ± 2.01, 0.83 ± 
0.07, 22.26 ± 1.02, 2.10 ± 2.15, 2.57 ± 0.99 respectively in groupIIa (table I) and 
194.36 ± 35.52, 122.71 ± 53.73, 43.49 ± 10.38, 110.64 ± 43.63, 8.74 ± 9.83, 0.89 
± 0.05, 33.43 ± 4.34, 4.05 ± 2.71, 2.60 ± 1.08 respectively in groupIIb(table I). 
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       DISCUSSION 
Obesity is known to affect host immunity ( Tanaka et al,1993, Stallone, 1994). 
Upper body obesity (abdominal obesity) is believed to have greater ill-effects on health 
than lower body obesity (Vanhala et al., 1997; Rexrode et al 1998). The visceral fat 
accumulation that is frequently observed in upper body obesity increases the risk of 
cardiovascular diseases (Nakamura et al., 1994) and type 2 diabetes (Banerji et al 
,1995). An increase in visceral fat is associated with insulin resistance and increased liver 
fat (Banerji et al, 1995; Goto et al 1995). 
Previous studies have showed a significant association between periodontitis  and 
serum levels of AST, ALT, and  cholinesterase suggesting that subjects with periodontitis 
also tend to have hepatic steatosis. Visceral fat, which leads to hepatic steatosis may also 
increase the risk of periodontitis. 
Tumor necrosis factor α (TNF- α) mediates endotoxin induced injury in various 
organs and periodontal treatment (Gemmel et al ,1997). Among these organs, the liver is 
most involved in lipid metabolism. Adipose tissue also secretes TNF- α , which causes 
liver injury in obese rodents (Yang et al ,1997). Moreover TNF- α from adipose tissue 
was reported to be directly associated with insulin resistance (Hotamisligil et al., 1996; 
Uysal et al., 1997). An increase in hepatic triglyceride is dependent on an influx of free 
fatty acids, which are mainly derived from visceral adipose tissue, and is associated with 
insulin resistance (Kopelman, 2000). Several studies have indicated that hyperlipidemia 
frequently accompanies infectious diseases (Feingold et al., 1992; Hardardottir al., 
1994). A single dose of bacterial endotoxin (LPS) can induce changes in lipid metabolism 
in adipose tissue and in the liver (Feingold et al., 1992). 
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Recently, an association between periodontitis and hyperlipidemia was reported 
(Cutler et al., 1999). If LPS derived from Gram-negative bacteria in periodontal pockets 
mediates TNF- α release from adipose tissue, it may be associated with hepatic 
dyslipidemia. Hepatic dyslipidemia induced by periodontal pathogens could be 
associated with insulin resistance. 
In the present study both sexes were included similar to other studies (Cutler 
1999
 
, Joseph Katz 2002, Katz 2001 Loesche 2000). 
The sample selected in this study was within the age group of 18 to 34 years for  
younger  age  group and  35  to 59  years   for  middle  age  group   was  accordance  with  
the  study  done  by (Al.Zaharani MS   et  al 2003) .  
The other confounding factors related to elevated cholesterol level like smoking, 
hypertension, lever disease were eliminated in the present study similar to earlier studies. 
(Loesche 2000). 
According to Katz et al 2002 smoking status is positively correlated with TC, 
LDL and TGL and negatively associated with HDL cholesterol. Vasoconstriction of 
gingival blood vessels caused by smoking promoted invasion of periodontal disease by 
microorganism (Loesche 1998), Hence smokers was excluded from the study. 
Visceral fat accumulation raises the risk of cardiovascular disease more than does 
subcutaneous fat (Nakamura et al., 1994). Thereafter, a higher waist-hip ratio has been 
reported to increase this risk independently of BMI (Rexrode et al., 1998). 
BMI is highly correlated with fat mass however, there are some limitations. For 
example, for the same BMI, older persons tend to have a higher body fat composition, 
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and, therefore, risk assessment by BMI is less accurate in older people (over 65 yrs of 
age). Furthermore, current BMI cut-off points for overweight and obesity are probably 
too high for Asian populations (Table 2) (Choo, 2002). More importantly, the BMI does 
not assess body fat distribution. 
In this study both Body Mass Index and Central obesity were assessed as Clinical 
indicators of obesity. Blood lipid profile was estimated to assess the lipidaemic status of 
the subjects and levels of serum C reactive protein was estimated as systemic 
inflammatory marker associated with both obesity and periodontitis. 
In group Ia, the average BMI was 20.83 (SD 1.71) and all the clinical and 
biochemical parameters were within the normal limits (Table I). In group IIb, the mean 
BMI was 30.97 (SD 6.14) which lies in the obesity range and the mean CAL was 1.29 
(SD 1.62). Subjects in group IIb demonstrated increased CRP values of 5.36 (SD 4.45) 
(Table I).There was a positive correlation between CRP levels and the severity of 
periodontitis but the results were not statistically significant. In group IIa the mean BMI 
was 22.26(SD 1.02) and the mean CAL was 2.1(SD 2.15) which infers mild periodontitis 
was prevalent among the subjects and mean CRP level was 2.18±2.01 which was within 
the normal limits(Table I). In group IIb the mean BMI was33.43±4.34 and the mean CAL 
was 4.05±2.71.Even though there was a high degree of attachment loss and  positive 
correlation  the results were not statistically significant(Table I). This is in accordance 
with the studies done by Saito et al, 2001 who concluded  BMI was positively correlated 
with severity of periodontitis after adjustment with age and socioeconomic status. In the 
NHANES III portion of the study, BMI was positively related to the severity of 
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periodontal attachment loss. (Robert J. Genco et al 2005). Both smoking and obesity are 
independent risk indicators for periodontitis. (Nishida et al 2005). 
Previous studies of the risk of cardiovascular disease with periodontitis adjusted 
the risk by using BMI as a conventional index of obesity (Joshipura et al., 1996; Beck 
et al.,, 2000; Mattila et al., 2000). The risk of cardiovascular disease with periodontitis 
should be reconsidered, since visceral fat accumulation appears to be related to both 
diseases and may be a confounding factor. The mean values of waist hip ratio among 
males is 0.83 ± 0.03, 0.97 ± 0.02, 0.87 ± 0.03 and 0.81 in groups Ia, Ib, IIa and IIb 
respectively while for the females 0.75 ± 0.03, 0.88 ± 0.11, 0.77 ± 0.06, 0.89 ± 0.05 in 
groups Ia, Ib, IIa and IIb respectively (Table XIX). In group IIa the waist hip ratio had 
significant positive correlation with CAL without gender predilection (p < 0.05) (Table 
no II). There was similar positive correlation in group IIb as well without gender 
predilection (p < 0.05). There was no statistical significance between waist hip ratio and 
CAL levels in group Ia and Ib categories(Table II). This infers that the CAL is mainly 
age related and central obesity could be an additional factor when combined with 
advancing age for periodontitis. 
Previous studies have indicated that patients with adult periodontitis often have 
elevated serum triglyceride and LDL levels. (Cutler et al 1990). Results of studies done 
by Cutler et al  has proved that significant positive relationship exists between 
periodontitis and elevated serum levels of triglycerides and IgG antibodies against 
P.gingivalis LPS. Moreover TG can increase the amount of IL-1β released by PMN’s in 
response to P.gingivalis LPS. (Cutler,  Edward et al 1999).  
 
 
54 
 
The mean values of TC in the present study are 150.40±22.6, 164.96±34.33,  
184.32±32.38 and 194.36±35.52 among group Ia, Ib, IIa and IIb respectively. (Table I) 
The mean values of TG  in the present study are 70.28 ± 30.90, 97.84±58.11, 
101.16±43.90 and 122.71±53.73 among group Ia, Ib, IIa and IIb respectively. (Table I) 
The mean values of HDL  in the present study are 44.28 ± 11.66, 36.13±11.31, 
42.31±13.45 and 43.49±10.38 among group Ia, Ib, IIa and IIb respectively. (Table I) 
The mean values of LDL  in the present study are 82.36 ± 25.92, 77.67±36.02, 
101.52±36.28 and 110.64±43.63 among group Ia, Ib, IIa and IIb respectively. (Table I) 
The mean values of LDL/HDL ratio in the present study are 1.95 ± 0.69, 
2.20±0.99, 2.57±0.99 and 2.60±1.08 among group Ia, Ib, IIa and IIb respectively. (Table 
I) 
 In the present study the mean lipid profile had no statistically significant 
correlation with the CAL in all the groups. The mean values of the lipid profile  in 
the present study are within the normal limits and hence could be a possible reason 
for not achieving statistically significant positive correlation with CAL. (Table II) 
On the contrary studies have indicated that increased serum TG has a negative 
influence on all the clinical measures of periodontal health particularly in patients without 
preexisting periodontitis. (Cutler . W, Robert .L et al 1999). 
Total cholesterol, LDL and TG were significantly higher in periodontally diseased 
subjects compared to controls. (Losche et al 2000). 
Studies conducted by Joseph Katz et al 2002 has concluded that the presence of 
periodontal pockets as measured by CPITN was positively associated with total 
cholesterol and LDL. 
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The mean values of hsCRP in the present study are 1.66 ± 1.86, 5.36±4.45, 
2.18±2.01 and 8.74±9.83 among group Ia, Ib, IIa and IIb respectively. (Table I) The 
hsCRP levels are highly positively statistically significant correlation with the CAL 
measurement in group Ib subjects. (Table II) This may infer that increased CRP levels in 
younger age group subjects with high BMI could be a possible risk indicator for 
increased attachment loss. Hence it may be hypothesized here that increased BMI at an 
younger age group can pose an increased risk for periodontitis and attachment loss. 
This study is in agreement with Al-Zahrani et al 2003 who stated that in younger 
population overall and abdominal obesity are associated with increased prevalence of 
periodontal disease. 
Numerous studies have shown a positive association between chronic 
periodontitis and elevated CRP levels (Ebersole et al, 1997, Ide et al 2004, D,Aiuto 
2005, Pussinen et al 2005). 
According to American Journal of Cardiology & Journal of Periodontology, 
2009, patients with periodontitis meeting criteria for metabolic syndrome should be 
identified and all the risk factors for atherosclerotic CVD should be treated, beginning 
with lifestyle changes aimed at weight reduction. 
Finally, although longitudinal evaluation with a larger population may be an 
important step in revealing the causal relationship between periodontal disease and 
obesity, impaired lipid metabolism   our study may shed light on the clarification of this 
association in the future. 
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Tables I: Mean values of the parameters assessed in the study 
  Group 
  Group IA Group IB Group 2A Group 2B 
  Mean SD Mean SD Mean SD Mean SD 
TC 150.40 22.66 164.96 34.33 184.32 32.38 194.36 35.52 
TGL 70.28 30.90 97.84 58.11 101.16 43.90 122.71 53.73 
HDL 44.28 11.66 36.13 11.31 42.31 13.45 43.49 10.38 
LDL 82.96 25.92 77.67 36.02 101.52 36.28 110.64 43.63 
HSCRP 1.66 1.86 5.36 4.45 2.18 2.01 8.74 9.83 
WHRatio .79 .05 .90 .11 .83 .07 .89 .05 
BMI_A 20.83 1.71 30.97 6.14 22.26 1.02 33.43 4.34 
PD 2.21 .54 3.36 1.11 3.74 1.74 4.77 1.52 
CAL .16 .41 1.29 1.62 2.10 2.15 4.05 2.71 
BI 20.70 21.72 63.20 30.65 58.08 31.61 84.76 24.31 
PI .48 .54 1.22 .73 1.46 .85 1.96 .87 
LDL / 
HDL 
1.95 .69 2.20 .99 2.57 .99 2.60 1.08 
 
 
Table II Association between biochemical, clinical and periodontal parameters in 
group Ia 
    PD CAL BI 
TC Pearson Correlation 
-.345 -.363 -.449(*) 
Sig. (2-tailed) 
.091 .074 .024 
N 
25 25 25 
TGL Pearson Correlation 
.165 .155 .021 
Sig. (2-tailed) 
.430 .460 .919 
N 
25 25 25 
HDL Pearson Correlation 
-.232 -.249 -.224 
Sig. (2-tailed) 
.264 .229 .281 
N 
25 25 25 
LDL Pearson Correlation 
-.366 -.318 -.417(*) 
Sig. (2-tailed) 
.072 .122 .038 
N 
25 25 25 
HSCRP Pearson Correlation 
.018 .131 .022 
Sig. (2-tailed) 
.932 .532 .915 
N 
25 25 25 
WHRatio Pearson Correlation 
-.037 .260 .057 
Sig. (2-tailed) 
.862 .210 .787 
N 
25 25 25 
BMI_A Pearson Correlation 
.036 .354 .090 
Sig. (2-tailed) 
.866 .083 .667 
N 
25 25 25 
LDL / HDL Pearson Correlation 
-.178 -.103 -.244 
Sig. (2-tailed) 
.394 .624 .240 
N 
25 25 25 
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TableIII  : ASSOCIATION BETWEEN BIOCHEMICAL, CLINICAL AND PERIODONTAL PARAMETERS 
IN GROUP IB 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    PD CAL BI 
TC Pearson Correlation 
-.407(*) -.336 -.226 
Sig. (2-tailed) 
.044 .101 .278 
N 
25 25 25 
TGL Pearson Correlation 
.058 .155 .033 
Sig. (2-tailed) 
.782 .458 .876 
N 
25 25 25 
HDL Pearson Correlation 
-.347 -.169 -.422(*) 
Sig. (2-tailed) 
.089 .418 .036 
N 
25 25 25 
LDL Pearson Correlation 
-.230 -.024 -.137 
Sig. (2-tailed) 
.269 .911 .515 
N 
25 25 25 
HSCRP Pearson Correlation 
.485(*) .524(**) .347 
Sig. (2-tailed) 
.014 .007 .089 
N 
25 25 25 
WHRatio Pearson Correlation 
.101 .100 .323 
Sig. (2-tailed) 
.631 .634 .115 
N 
25 25 25 
BMI_A Pearson Correlation 
.139 .066 .417(*) 
Sig. (2-tailed) 
.509 .753 .038 
N 
25 25 25 
LDL / HDL Pearson Correlation 
-.002 .089 .192 
Sig. (2-tailed) 
.993 .674 .357 
N 
25 25 25 
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Table IV :  Association Between Biochemical, Clinical And Periodontal Parameters 
In Group IIa 
 
  
    PD CAL BI 
TC Pearson 
Correlation 
-.131 -.092 -.226 
Sig. (2-tailed) .533 .663 .278 
N 25 25 25 
TGL Pearson 
Correlation 
.078 .112 .014 
Sig. (2-tailed) .712 .593 .945 
N 25 25 25 
HDL Pearson 
Correlation 
.002 -.021 -.169 
Sig. (2-tailed) .993 .920 .418 
N 25 25 25 
LDL Pearson 
Correlation 
-.156 -.090 -.310 
Sig. (2-tailed) .456 .667 .132 
N 25 25 25 
HSCRP Pearson 
Correlation 
.167 .104 .327 
Sig. (2-tailed) .424 .620 .111 
N 25 25 25 
WHRatio Pearson 
Correlation 
.392 .408(*) .374 
Sig. (2-tailed) .053 .043 .066 
N 25 25 25 
BMI_A Pearson 
Correlation 
.154 .146 .161 
Sig. (2-tailed) .463 .486 .441 
N 25 25 25 
LDL / HDL Pearson 
Correlation 
-.248 -.153 -.240 
Sig. (2-tailed) .233 .464 .249 
N 25 25 25 
*  Correlation is significant at the 0.05 level (2-tailed). 
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Table V : Association Between Biochemical, Clinical And Periodontal Parameters In 
Group IIb 
 
 
    PD CAL BI 
TC Pearson 
Correlation 
.111 -.075 .324 
Sig. (2-tailed) .596 .723 .114 
N 25 25 25 
TGL Pearson 
Correlation 
-.226 -.148 .259 
Sig. (2-tailed) .277 .480 .211 
N 25 25 25 
HDL Pearson 
Correlation 
.257 .103 .221 
Sig. (2-tailed) .215 .625 .288 
N 25 25 25 
LDL Pearson 
Correlation 
.109 .017 .227 
Sig. (2-tailed) .603 .934 .276 
N 25 25 25 
HSCRP Pearson 
Correlation 
-.010 .392 .265 
Sig. (2-tailed) .963 .053 .201 
N 25 25 25 
WHRatio Pearson 
Correlation 
.294 .417(*) .003 
Sig. (2-tailed) .154 .038 .990 
N 25 25 25 
BMI_A Pearson 
Correlation 
.194 .040 .077 
Sig. (2-tailed) .353 .848 .714 
N 25 25 25 
LDL / HDL Pearson 
Correlation 
-.148 -.138 -.016 
Sig. (2-tailed) .479 .511 .938 
N 25 25 25 
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TABLE VI:Distribution Of Severity Of Periodontitis Among The Study Groups: 
 
  
 
    
CAL Group 
Total 0-1 1-3 3-5 Above 5 
Group Group IA Count 
23 2 0 0 25 
% within 
Group 
92.0% 8.0% .0% .0% 100.0% 
% within CAL 
Group 
44.2% 10.5% .0% .0% 25.0% 
Group IB Count 
16 4 4 1 25 
% within 
Group 
64.0% 16.0% 16.0% 4.0% 100.0% 
% within CAL 
Group 
30.8% 21.1% 28.6% 6.7% 25.0% 
Group 2A Count 
9 8 4 4 25 
% within 
Group 
36.0% 32.0% 16.0% 16.0% 100.0% 
% within CAL 
Group 
17.3% 42.1% 28.6% 26.7% 25.0% 
Group 2B Count 
4 5 6 10 25 
% within 
Group 
16.0% 20.0% 24.0% 40.0% 100.0% 
% within CAL 
Group 
7.7% 26.3% 42.9% 66.7% 25.0% 
Total Count 
52 19 14 15 100 
% within 
Group 
52.0% 19.0% 14.0% 15.0% 100.0% 
% within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE VII: Prevalence of periodontitis with respect to TC levels: 
Group     CAL Group Total 
    0-1 1-3 3-5 
Above 
5   
Group IA TC - Group Below 200 Count 23 2     25 
      % within TC  -  92.0% 8.0%     100.0% 
      % within CAL 
Group 
100.0% 100.0%     100.0% 
  Total Count 23 2     25 
  % within TC - 
Group 
92.0% 8.0%     100.0% 
  % within CAL 
Group 
100.0% 100.0%     100.0% 
Group IB TC - Group Below 200 Count 12 3 4 1 20 
      % within TC - 
Group 
60.0% 15.0% 20.0% 5.0% 100.0% 
      % within CAL 
Group 
75.0% 75.0% 100.0% 100.0% 80.0% 
    Above 200 Count 4 1 0 0 5 
      % within TC - 
Group 
80.0% 20.0% .0% .0% 100.0% 
      % within CAL 
Group 
25.0% 25.0% .0% .0% 20.0% 
  Total Count 16 4 4 1 25 
  % within TC - 
Group 
64.0% 16.0% 16.0% 4.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2A TC - Group Below 200 Count 6 6 2 4 18 
      % within TC - 
Group 
33.3% 33.3% 11.1% 22.2% 100.0% 
      % within CAL 
Group 
66.7% 75.0% 50.0% 100.0% 72.0% 
    Above 200 Count 3 2 2 0 7 
      % within TC - 
Group 
42.9% 28.6% 28.6% .0% 100.0% 
      % within CAL 
Group 
33.3% 25.0% 50.0% .0% 28.0% 
  Total Count 9 8 4 4 25 
  % within TC - 
Group 
36.0% 32.0% 16.0% 16.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2B TC - Group Below 200 Count 2 4 5 7 18 
      % within TC - 
Group 
11.1% 22.2% 27.8% 38.9% 100.0% 
      % within CAL 
Group 
50.0% 80.0% 83.3% 70.0% 72.0% 
    Above 200 Count 2 1 1 3 7 
      % within TC - 
Group 
28.6% 14.3% 14.3% 42.9% 100.0% 
      % within CAL 
Group 
50.0% 20.0% 16.7% 30.0% 28.0% 
  Total Count 4 5 6 10 25 
  % within TC - 
Group 
16.0% 20.0% 24.0% 40.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE VIII: CORRELATION BETWEEN TC AND CAL 
 
Group   Value df 
Asymp. Sig. 
(2-sided) 
Group IA Pearson Chi-
Square 
.(a)     
N of Valid Cases 25     
Group IB Pearson Chi-
Square 
1.562(b) 3 .668 
  Likelihood Ratio 2.527 3 .470 
Linear-by-Linear 
Association 
1.200 1 .273 
N of Valid Cases 25     
Group 2A Pearson Chi-
Square 
2.679(c) 3 .444 
  Likelihood Ratio 3.648 3 .302 
Linear-by-Linear 
Association 
.563 1 .453 
N of Valid Cases 25     
Group 2B Pearson Chi-
Square 
1.521(d) 3 .677 
  Likelihood Ratio 1.474 3 .688 
Linear-by-Linear 
Association 
.209 1 .647 
N of Valid Cases 
25     
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TABLE IX: Prevalence of periodontitis with respect to LDL levels: 
Group     CAL Group Total 
    0-1 1-3 3-5 Above 5   
Group IA LDL - Group Below 130 Count 22 2     24 
      % within LDL - 
Group 
91.7% 8.3%     100.0% 
      % within CAL 
Group 
95.7% 100.0%     96.0% 
    Above 130 Count 1 0     1 
      % within LDL - 
Group 
100.0% .0%     100.0% 
      % within CAL 
Group 
4.3% .0%     4.0% 
  Total Count 23 2     25 
  % within LDL - 
Group 
92.0% 8.0%     100.0% 
  % within CAL 
Group 
100.0% 100.0%     100.0% 
ssGroup IB LDL - Group Below 130 Count 15 4 4 1 24 
      % within LDL - 
Group 
62.5% 16.7% 16.7% 4.2% 100.0% 
      % within CAL 
Group 
93.8% 100.0% 100.0% 100.0% 96.0% 
    Above 130 Count 1 0 0 0 1 
      % within LDL - 
Group 
100.0% .0% .0% .0% 100.0% 
      % within CAL 
Group 
6.3% .0% .0% .0% 4.0% 
  Total Count 16 4 4 1 25 
  % within LDL - 
Group 
64.0% 16.0% 16.0% 4.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2A LDL - Group Below 130 Count 6 6 3 4 19 
      % within LDL - 
Group 
31.6% 31.6% 15.8% 21.1% 100.0% 
      % within CAL 
Group 
66.7% 75.0% 75.0% 100.0% 76.0% 
    Above 130 Count 3 2 1 0 6 
      % within LDL - 
Group 
50.0% 33.3% 16.7% .0% 100.0% 
      % within CAL 
Group 
33.3% 25.0% 25.0% .0% 24.0% 
  Total Count 9 8 4 4 25 
  % within LDL - 
Group 
36.0% 32.0% 16.0% 16.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2B LDL - Group Below 130 Count 2 3 5 6 16 
      % within LDL - 
Group 
12.5% 18.8% 31.3% 37.5% 100.0% 
      % within CAL 
Group 
50.0% 60.0% 83.3% 60.0% 64.0% 
    Above 130 Count 2 2 1 4 9 
      % within LDL - 
Group 
22.2% 22.2% 11.1% 44.4% 100.0% 
      % within CAL 
Group 
50.0% 40.0% 16.7% 40.0% 36.0% 
  Total Count 4 5 6 10 25 
  % within LDL - 
Group 
16.0% 20.0% 24.0% 40.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE X: CORRELATION BETWEEN LDL AND CAL 
 
Group   Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Group IA Pearson Chi-
Square 
.091(b) 1 .763     
Continuity 
Correction(a) 
.000 1 1.000     
Likelihood Ratio .170 1 .680     
Fisher's Exact 
Test 
      1.000 .920 
Linear-by-Linear 
Association 
.087 1 .768     
N of Valid Cases 25         
Group IB Pearson Chi-
Square 
.586(c) 3 .900     
Likelihood Ratio .916 3 .822     
Linear-by-Linear 
Association 
.450 1 .502     
N of Valid Cases 25         
Group 2A Pearson Chi-
Square 
1.700(d) 3 .637     
  Likelihood Ratio 2.601 3 .457     
Linear-by-Linear 
Association 
1.360 1 .244     
N of Valid Cases 25         
Group 2B Pearson Chi-
Square 
1.418(e) 3 .701     
  Likelihood Ratio 1.529 3 .676     
Linear-by-Linear 
Association 
.115 1 .734     
N of Valid Cases 25         
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TABLE XI: Prevalence of periodontitis with respect to HDL levels: 
Group     CAL Group Total 
    0-1 1-3 3-5 
Above 
5   
Group IA HDL - Group Below 27 Count 1 0     1 
      % within HDL - 
Group 
100.0% .0%     100.0% 
      % within CAL 
Group 
4.3% .0%     4.0% 
    Above 27 Count 22 2     24 
      % within HDL - 
Group 
91.7% 8.3%     100.0% 
      % within CAL 
Group 
95.7% 100.0%     96.0% 
  Total Count 23 2     25 
  % within HDL - 
Group 
92.0% 8.0%     100.0% 
  % within CAL 
Group 
100.0% 100.0%     100.0% 
Group IB HDL - Group Below 27 Count 3 1 0 0 4 
      % within HDL - 
Group 
75.0% 25.0% .0% .0% 100.0% 
      % within CAL 
Group 
18.8% 25.0% .0% .0% 16.0% 
    Above 27 Count 13 3 4 1 21 
      % within HDL - 
Group 
61.9% 14.3% 19.0% 4.8% 100.0% 
      % within CAL 
Group 
81.3% 75.0% 100.0% 100.0% 84.0% 
  Total Count 16 4 4 1 25 
  % within HDL - 
Group 
64.0% 16.0% 16.0% 4.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2A HDL - Group Below 27 Count 0 1 0 0 1 
      % within HDL - 
Group 
.0% 100.0% .0% .0% 100.0% 
      % within CAL 
Group 
.0% 12.5% .0% .0% 4.0% 
    Above 27 Count 9 7 4 4 24 
      % within HDL - 
Group 
37.5% 29.2% 16.7% 16.7% 100.0% 
      % within CAL 
Group 
100.0% 87.5% 100.0% 100.0% 96.0% 
  Total Count 9 8 4 4 25 
  % within HDL - 
Group 
36.0% 32.0% 16.0% 16.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2B HDL - Group Below 27 Count 1 0 0 0 1 
      % within HDL - 
Group 
100.0% .0% .0% .0% 100.0% 
      % within CAL 
Group 
25.0% .0% .0% .0% 4.0% 
    Above 27 Count 3 5 6 10 24 
      % within HDL - 
Group 
12.5% 20.8% 25.0% 41.7% 100.0% 
      % within CAL 
Group 
75.0% 100.0% 100.0% 100.0% 96.0% 
  Total Count 4 5 6 10 25 
  % within HDL - 
Group 
16.0% 20.0% 24.0% 40.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE XII : CORRELATION BETWEEN HDL AND CAL 
 
Group   Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Group IA Pearson Chi-
Square 
.091(b) 1 .763     
Continuity 
Correction(a) 
.000 1 1.000     
Likelihood Ratio .170 1 .680     
Fisher's Exact 
Test 
      1.000 .920 
Linear-by-Linear 
Association 
.087 1 .768     
N of Valid Cases 25         
Group IB Pearson Chi-
Square 
1.283(c) 3 .733     
Likelihood Ratio 2.042 3 .564     
Linear-by-Linear 
Association 
.700 1 .403     
N of Valid Cases 25         
Group 2A Pearson Chi-
Square 
2.214(d) 3 .529     
  Likelihood Ratio 2.369 3 .499     
Linear-by-Linear 
Association 
.013 1 .911     
N of Valid Cases 25         
Group 2B Pearson Chi-
Square 
5.469(d) 3 .141     
  Likelihood Ratio 3.899 3 .273     
Linear-by-Linear 
Association 
2.884 1 .089     
N of Valid Cases 25         
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TABLE XIII: Prevalence of periodontitis with respect to TGL levels 
Group     CAL Group Total 
    0-1 1-3 3-5 Above 5   
Group IA TGL – Group Below 150 Count 
23 1     24 
      % within 
TGL - Group 
95.8% 4.2%     100.0% 
      % within 
CAL Group 
100.0% 50.0%     96.0% 
    Above 150 Count 
0 1     1 
      % within 
TGL - Group 
.0% 100.0%     100.0% 
      % within 
CAL Group 
.0% 50.0%     4.0% 
  Total Count 
23 2     25 
  % within 
TGL - Group 
92.0% 8.0%     100.0% 
  % within 
CAL Group 
100.0% 100.0%     100.0% 
Group IB TGL - Group Below 150 Count 
13 4 3 1 21 
      % within 
TGL - Group 
61.9% 19.0% 14.3% 4.8% 100.0% 
      % within 
CAL Group 
81.3% 100.0% 75.0% 100.0% 84.0% 
    Above 150 Count 
3 0 1 0 4 
      % within 
TGL - Group 
75.0% .0% 25.0% .0% 100.0% 
      % within 
CAL Group 
18.8% .0% 25.0% .0% 16.0% 
  Total Count 
16 4 4 1 25 
  % within 
TGL - Group 
64.0% 16.0% 16.0% 4.0% 100.0% 
  % within 
CAL Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2A TGL - Group Below 150 Count 
7 7 4 3 21 
      % within 
TGL - Group 
33.3% 33.3% 19.0% 14.3% 100.0% 
      % within 
CAL Group 
77.8% 87.5% 100.0% 75.0% 84.0% 
    Above 150 Count 
2 1 0 1 4 
      % within 
TGL - Group 
50.0% 25.0% .0% 25.0% 100.0% 
      % within 
CAL Group 
22.2% 12.5% .0% 25.0% 16.0% 
  Total Count 
9 8 4 4 25 
  % within 
TGL - Group 
36.0% 32.0% 16.0% 16.0% 100.0% 
  % within 
CAL Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2B TGL - Group Below 150 Count 
4 3 3 7 17 
      % within 
TGL - Group 
23.5% 17.6% 17.6% 41.2% 100.0% 
      % within 
CAL Group 
100.0% 60.0% 50.0% 70.0% 68.0% 
    Above 150 Count 
0 2 3 3 8 
      % within 
TGL - Group 
.0% 25.0% 37.5% 37.5% 100.0% 
      % within 
CAL Group 
.0% 40.0% 50.0% 30.0% 32.0% 
  Total Count 
4 5 6 10 25 
  % within 
TGL - Group 
16.0% 20.0% 24.0% 40.0% 100.0% 
  % within 
CAL Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE XIV: CORRELATION BETWEEN TGL AND CAL 
 
Group   Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Group IA Pearson Chi-
Square 
11.979(b) 1 .001     
Continuity 
Correction(a) 
2.497 1 .114     
Likelihood Ratio 5.625 1 .018     
Fisher's Exact 
Test 
      .080 .080 
Linear-by-Linear 
Association 
11.500 1 .001     
N of Valid Cases 25         
Group IB Pearson Chi-
Square 
1.283(c) 3 .733     
Likelihood Ratio 2.042 3 .564     
Linear-by-Linear 
Association 
.057 1 .811     
N of Valid Cases 25         
Group 2A Pearson Chi-
Square 
1.335(d) 3 .721     
  Likelihood Ratio 1.922 3 .589     
Linear-by-Linear 
Association 
.057 1 .811     
N of Valid Cases 25         
Group 2B Pearson Chi-
Square 
2.941(e) 3 .401     
  Likelihood Ratio 4.078 3 .253     
Linear-by-Linear 
Association 
.553 1 .457     
N of Valid Cases 25         
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TABLE XV: Prevalence of periodontitis with respect to HDL/LDL ratio levels 
Group     CAL Group Total 
    0-1 1-3 3-5 Above 5   
Group IA LDL / HDL Below 3.5 Count 23 2     25 
      % within 
LDL / HDL 
92.0% 8.0%     100.0% 
      % within 
CAL Group 
100.0% 100.0%     100.0% 
  Total Count 23 2     25 
  % within 
LDL / HDL 
92.0% 8.0%     100.0% 
  % within 
CAL Group 
100.0% 100.0%     100.0% 
Group IB LDL / HDL Below 3.5 Count 15 3 3 1 22 
      % within 
LDL / HDL 
68.2% 13.6% 13.6% 4.5% 100.0% 
      % within 
CAL Group 
93.8% 75.0% 75.0% 100.0% 88.0% 
    Above 3.5 Count 1 1 1 0 3 
      % within 
LDL / HDL 
33.3% 33.3% 33.3% .0% 100.0% 
      % within 
CAL Group 
6.3% 25.0% 25.0% .0% 12.0% 
  Total Count 16 4 4 1 25 
  % within 
LDL / HDL 
64.0% 16.0% 16.0% 4.0% 100.0% 
  % within 
CAL Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2A LDL / HDL Below 3.5 Count 7 7 4 3 21 
      % within 
LDL / HDL 
33.3% 33.3% 19.0% 14.3% 100.0% 
      % within 
CAL Group 
77.8% 87.5% 100.0% 75.0% 84.0% 
    Above 3.5 Count 2 1 0 1 4 
      % within 
LDL / HDL 
50.0% 25.0% .0% 25.0% 100.0% 
      % within 
CAL Group 
22.2% 12.5% .0% 25.0% 16.0% 
  Total Count 9 8 4 4 25 
  % within 
LDL / HDL 
36.0% 32.0% 16.0% 16.0% 100.0% 
  % within 
CAL Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2B LDL / HDL Below 3.5 Count 2 4 5 9 20 
      % within 
LDL / HDL 
10.0% 20.0% 25.0% 45.0% 100.0% 
      % within 
CAL Group 
50.0% 80.0% 83.3% 90.0% 80.0% 
    Above 3.5 Count 2 1 1 1 5 
      % within 
LDL / HDL 
40.0% 20.0% 20.0% 20.0% 100.0% 
      % within 
CAL Group 
50.0% 20.0% 16.7% 10.0% 20.0% 
  Total Count 4 5 6 10 25 
  % within 
LDL / HDL 
16.0% 20.0% 24.0% 40.0% 100.0% 
  % within 
CAL Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE XVI: CORRELATION BETWEEN LDL/HDL AND CAL 
 
Group   Value df 
Asymp. Sig. 
(2-sided) 
Group IA Pearson Chi-
Square 
.(a)     
N of Valid Cases 25     
Group IB Pearson Chi-
Square 
1.918(b) 3 .590 
  Likelihood Ratio 1.868 3 .600 
Linear-by-Linear 
Association 
.655 1 .418 
N of Valid Cases 25     
Group 2A Pearson Chi-
Square 
1.335(c) 3 .721 
  Likelihood Ratio 1.922 3 .589 
Linear-by-Linear 
Association 
.057 1 .811 
N of Valid Cases 25     
Group 2B Pearson Chi-
Square 
2.917(d) 3 .405 
  Likelihood Ratio 2.563 3 .464 
Linear-by-Linear 
Association 
2.264 1 .132 
N of Valid Cases 
25     
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TABLE XVII:  Prevalence of periodontitis with respect to hscrp levels 
Group     CAL Group Total 
    0-1 1-3 3-5 Above 5   
Group IA HSCRP Below 3 Count 
21 1     22 
      % within HSCRP 
95.5% 4.5%     100.0% 
      % within CAL 
Group 
91.3% 50.0%     88.0% 
    3-10 Count 
2 1     3 
      % within HSCRP 
66.7% 33.3%     100.0% 
      % within CAL 
Group 
8.7% 50.0%     12.0% 
  Total Count 23 2     25 
  % within HSCRP 92.0% 8.0%     100.0% 
  % within CAL 
Group 
100.0% 100.0%     100.0% 
Group IB HSCRP Below 3 Count 
8 1 1 0 10 
      % within HSCRP 
80.0% 10.0% 10.0% .0% 100.0% 
      % within CAL 
Group 
50.0% 25.0% 25.0% .0% 40.0% 
    3-10 Count 
6 2 1 0 9 
      % within HSCRP 
66.7% 22.2% 11.1% .0% 100.0% 
      % within CAL 
Group 
37.5% 50.0% 25.0% .0% 36.0% 
    Above 10 Count 
2 1 2 1 6 
      % within HSCRP 
33.3% 16.7% 33.3% 16.7% 100.0% 
      % within CAL 
Group 
12.5% 25.0% 50.0% 100.0% 24.0% 
  Total Count 
16 4 4 1 25 
  % within HSCRP 
64.0% 16.0% 16.0% 4.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2A HSCRP Below 3 Count 
9 4 4 2 19 
      % within HSCRP 
47.4% 21.1% 21.1% 10.5% 100.0% 
      % within CAL 
Group 
100.0% 50.0% 100.0% 50.0% 76.0% 
    3-10 Count 
0 4 0 2 6 
      % within HSCRP 
.0% 66.7% .0% 33.3% 100.0% 
      % within CAL 
Group 
.0% 50.0% .0% 50.0% 24.0% 
  Total Count 
9 8 4 4 25 
  % within HSCRP 
36.0% 32.0% 16.0% 16.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
Group 2B HSCRP Below 3 Count 1 2 2 0 5 
      % within HSCRP 20.0% 40.0% 40.0% .0% 100.0% 
      % within CAL 
Group 
25.0% 40.0% 33.3% .0% 20.0% 
    3-10 Count 
3 1 4 4 12 
      % within HSCRP 
25.0% 8.3% 33.3% 33.3% 100.0% 
      % within CAL 
Group 
75.0% 20.0% 66.7% 40.0% 48.0% 
    Above 10 Count 
0 2 0 6 8 
      % within HSCRP 
.0% 25.0% .0% 75.0% 100.0% 
      % within CAL 
Group 
.0% 40.0% .0% 60.0% 32.0% 
  Total Count 
4 5 6 10 25 
  % within HSCRP 
16.0% 20.0% 24.0% 40.0% 100.0% 
  % within CAL 
Group 
100.0% 100.0% 100.0% 100.0% 100.0% 
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TABLE XVIII: CORRELATION BETWEEN  hsCRP AND CAL 
 
Group   Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. 
(2-sided) 
Exact Sig. 
(1-sided) 
Group IA Pearson Chi-
Square 
2.973(b) 1 .085     
Continuity 
Correction(a) 
.348 1 .555     
Likelihood Ratio 1.983 1 .159     
Fisher's Exact 
Test 
      .230 .230 
Linear-by-Linear 
Association 
2.854 1 .091     
N of Valid Cases 25         
Group IB Pearson Chi-
Square 
6.389(c) 6 .381     
Likelihood Ratio 6.027 6 .420     
Linear-by-Linear 
Association 
4.278 1 .039     
N of Valid Cases 25         
Group 2A Pearson Chi-
Square 
8.553(d) 3 .036     
  Likelihood Ratio 10.918 3 .012     
Linear-by-Linear 
Association 
1.977 1 .160     
N of Valid Cases 25         
Group 2B Pearson Chi-
Square 
11.326(e) 6 .079     
  Likelihood Ratio 15.794 6 .015     
Linear-by-Linear 
Association 
4.331 1 .037     
N of Valid Cases 25         
 
 
 
TABLE XIX: WHRatio  
 
  
Gender 
Male Female 
Mean SD Mean SD 
Group Group IA .83 .03 .75 .03 
Group IB .97 .02 .88 .11 
Group 2A .87 .03 .77 .06 
Group 2B .89 . .89 .05 
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FIGURE I: COMPARISION BETWEEN TC, TG ,HDL AND LDL IN 4 GROUPS: 
 
 
 
 
 
FIGURE II : COMPARISION BETWEEN HSCRP, WH RATIO, LDL/HDL BETWEEN 
4 GROUPS: 
 
 
 
 
 
 
 
 
 
 
 
 
TC
TG
HDL
LDL
0
20
40
60
80
100
120
140
160
180
200
GROUP IA
GROUP IB
GROUP IIA
GROUP IIB
TC
TG
HDL
LDL
 
 
 
74 
 
FIGURE III: PREVALENCE OF PERIODONTITIS AMONG 4 GROUPS: 
 
 
FIGURE IV: PREVALENCE OF PERIODONTITIS AMONG GENDER IN 4 
GROUPS: 
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FIGURE V: PREVALENCE OF PERIODONTITIS WITH RESPECT TO TC: 
 
 
FIGURE VI: PREVALENCE OF PERIODONTITIS WITH RESPECT TO TG: 
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FIGURE VII: PREVALENCE OF PERIODONTITIS WITH RESPECT TO HDL: 
 
 
FIGURE VIII: PREVALENCE OF PERIODONTITIS WITH RESPECT TO LDL: 
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FIGURE IX: PREVALENCE OF PERIODONTITIS WITH RESPECT TO LDL/HDL 
RATIO: 
 
 
FIGURE X: PREVALENCE OF PERIODONTITIS WITH RESPECT TO HSCRP: 
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FIGURE XI : WAIST HIP RATIO 
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                          SUMMARY AND CONCLUSION 
A total of 100 subjects were included in the study. The subjects were divided into 
2 groups based upon their age – 18 to 34 years and 35 to 59 years and further subdivided 
into 2 groups based on the BMI. A complete history was taken to rule out any other 
systemic diseases. A thorough periodontal examination was done which included plaque 
index, bleeding index, probing depth and clinical attachment levels. Clinical examination 
included measurement of BMI and waist hip ratio as indicators of obesity.  
Biochemical investigations included estimation of serum high sensitivity C reactive 
protein, total cholesterol, triglycerides, low density lipoprotein and high density 
lipoprotein. 
The results showed that there was a positive correlation between body mass index 
and waist hip ratio with clinical attachment levels but the results obtained were not 
statistically significant. This could be partly explained by the relatively smaller number 
of sample size included in the study. Futher studies including larger sample sizes may be 
conducted in obese patients adjusting for age, socioeconomic status and gender to 
evaluate the true relationship between obesity and periodontitis. 
Furthermore serum lipid profile was predominantly within the reference range in 
the study population. Hence it was difficult to draw conclusion between the lipidaemic 
status of the subjects for the severity of peridontitis. 
Finally there was a significant association between serum CRP levels with clinical 
attachment level in younger patients whose BMI was greater than 23. This may explain 
the fact that periodontitis may increase systemic inflammation in conjunction with 
obesity. 
